Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review
/in Dendritic Cells, International Publications, Ovarian CancerSuccessful treatment of advanced ovarian cancer with thermochemotherapy and adjuvant immune therapy
/in Dendritic Cells, Hyperthermia, International Publications, Ovarian CancerPre-clinical assessment of autologous DC-based therapy in ovarian cancer patients with progressive disease
/in Dendritic Cells, International Publications, Ovarian CancerSodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses
/in Hyperthermia, International Publications, Ovarian CancerPhase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission
/in Dendritic Cells, International Publications, Ovarian CancerA gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients
/in Dendritic Cells, International Publications, Ovarian CancerCombinatorial strategies for alleviation of tumor-associated immune suppression and therapeutic vaccination against ovarian cancer
/in Dendritic Cells, International Publications, Ovarian CancerDendritic cell vaccination against ovarian cancer–tipping the Treg/TH17 balance to therapeutic advantage?
/in Dendritic Cells, International Publications, Ovarian Cancer
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer